Fund+ Announces Investment in Ona Therapeutics – EUR30 Million Series A financing
Belgium, 16 June 2020: Fund+, an investment firm focused on innovative European Life Sciences companies, today announces that it has invested in a new portfolio company, Ona Therapeutics (Ona), which is focused on the discovery and development of therapeutic biologics to treat metastatic cancer. Alexandra Tolia, Partner at Fund+, will join the Board.
Ona Therapeutics was spun-out of IRB Barcelona and ICREA by co-founders Salvador Aznar-Benitah and Valerie Vanhooren, who was previously at Ablynx where she led drug development projects in collaboration with major pharmaceutical companies such as Merck and Abbvie. She studied at the VIB-Ghent University.